Monday, May 21, 2018

Risk-adapted therapy for #young #children with #medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)